Risk factors
Transcode Therapeutics (RNAZ) risk factors
Item 1A of every Transcode Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors120 risks14 new12 dropped20 reworded
Transcode Therapeutics acquired Polynoma in October 2025, adding Seviprotimut-L and new pipeline assets while taking on integration and financing risks.
Filed Apr 15, 2026 - FY2024 10-K risk factors118 risks
Transcode Therapeutics faces high risks from having no commercial products, substantial operating losses, and a critical need for near-term capital. Development of its lead oncology candidate, TTX-MC138, is at an early stage with substantial clinical and regulatory uncertainty.
Filed Apr 15, 2025